Insights from 2023 ASCO® Annual Meeting
H

ASCO® 2023 Insights: "PERSIST-2 Landmark OS Analysis - Spleen Volume Reduction Predicts OS in Myelofibrosis Pts on Pacritinib, But Not Best Available Therapy"

By Insights from 2023 ASCO® Annual Meeting FEATURING Helen Ajufo
By Insights from 2023 ASCO® Annual Meeting FEATURING Helen Ajufo
303 views
June 9, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Related Content

AUTOPLAY
27:37
Indy Hematology Review

Review of Myeloproliferative Neoplasms

Feat. A. Tefferi
24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
18:04
Ruben Mesa

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

21:52
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…

Feat. D. Tremblay
31:43
Indy Hematology Review

Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…

Feat. A. Tefferi
24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
10:02
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…

Feat. R. Mesa
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
12:18
Fred Hutchinson Cancer Center

Management of MPNs for the Community Oncologist

Feat. H. Deeg
16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
12:07
Douglas Tremblay

Monitoring Patients With MF: When to Switch Treatment

11:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

2024 Updates in Myeloproliferative Neoplasms

Feat. E. Hexner
24:48
Indy Hematology Review

2024 Updates on Myelofibrosis and Systemic Mastocytosis

Feat. R. Rampal
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry
15:31
Icahn School of Medicine at Mount Sinai

Myelofibrosis Treatment Options Beyond the JAK/STAT Pathway

Feat. M. Kremyanskaya
51:20
Jerry Spivak

Polycythemia Vera: Disease Overview, Treatment Landscape, and Curren…

53:01
PleXus Communications

Changing Pharmacological Paradigms for Higher-Risk Myelofibrosis

Feat. R. Rampal
11:09
Jeanne Palmer

Management of Clinical Manifestations in Myelofibrosis

15:41
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Addressing Anemia in Myelofibrosis

Feat. S. Oh
17:34
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Novel Non-JAK Inhibitor Therapies for Myelofibrosis

Feat. J. Mascarenhas